Rocket One Inc. Common Stock (NASDAQ:RKTO) versus Chipmos Technologies (NASDAQ:IMOS) Financial Contrast

Chipmos Technologies (NASDAQ:IMOS) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap technology companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Chipmos Technologies and Rocket One Inc. Common Stock, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chipmos Technologies	0	1	0	0	2.00
Rocket One Inc. Common Stock	1	0	1	0	2.00

Rocket One Inc. Common Stock has a consensus price target of $5.00, suggesting a potential upside of 557.98%. Given Rocket One Inc. Common Stock’s higher probable upside, analysts clearly believe Rocket One Inc. Common Stock is more favorable than Chipmos Technologies.

Risk & Volatility

Chipmos Technologies has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Rocket One Inc. Common Stock has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Institutional and Insider Ownership

7.4% of Chipmos Technologies shares are held by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 22.7% of Chipmos Technologies shares are held by insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Chipmos Technologies and Rocket One Inc. Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chipmos Technologies	3.05%	3.28%	1.76%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Valuation & Earnings

This table compares Chipmos Technologies and Rocket One Inc. Common Stock”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chipmos Technologies	$762.90 million	2.43	$17.55 million	$0.74	71.00
Rocket One Inc. Common Stock	N/A	N/A	-$12.47 million	($0.80)	-0.95

Chipmos Technologies has higher revenue and earnings than Rocket One Inc. Common Stock. Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Chipmos Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Chipmos Technologies beats Rocket One Inc. Common Stock on 10 of the 12 factors compared between the two stocks.

About Chipmos Technologies

ChipMOS TECHNOLOGIES INC. engages in the research, development, manufacture, and sale of high-integration and high-precision integrated circuits, and related assembly and testing services in the People’s Republic of China, Taiwan, Japan, Singapore, and internationally. It operates through Testing; Assembly; Testing and Assembly for LCD, OLED and Other Display Panel Driver Semiconductors; Bumping; and Others segments. The company provides a range of back-end assembly and testing services, including engineering test, wafer probing, and final test of memory and logic/mixed-signal semiconductors, as well as leadframe-based and organic substrate-based package assembly services for memory and logic/mixed-signal semiconductors; and gold bumping, and testing and assembly services for LCD, OLED, and other panel display driver semiconductors. Its semiconductors are used in personal computers; office automation and consumer electronics; and communications equipment applications. The company was incorporated in 1997 and is headquartered in Hsinchu City, Taiwan.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.